{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:49:47Z","timestamp":1779385787056,"version":"3.53.1"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1002\/pbc.25573","type":"journal-article","created":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T09:42:22Z","timestamp":1430386942000},"page":"1754-1760","source":"Crossref","is-referenced-by-count":20,"title":["Dose-level response rates of mTOR inhibition in tuberous sclerosis complex related subependymal giant cell astrocytoma"],"prefix":"10.1002","volume":"62","author":[{"given":"Danielle R.","family":"Weidman","sequence":"first","affiliation":[{"name":"Department of Paediatrics; The Hospital for Sick Children; Toronto Canada"},{"name":"University of Toronto; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Pole","sequence":"additional","affiliation":[{"name":"Child Health Evaluative Sciences; The Hospital for Sick Children; Toronto Canada"},{"name":"Pediatric Oncology Group of Ontario; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bouffet","sequence":"additional","affiliation":[{"name":"University of Toronto; Toronto Canada"},{"name":"Division of Haematology\/Oncology; Section of Neuro-Oncology; The Hospital for Sick Children; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Taylor","sequence":"additional","affiliation":[{"name":"University of Toronto; Toronto Canada"},{"name":"Division of Neurosurgery; The Hospital for Sick Children; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Bartels","sequence":"additional","affiliation":[{"name":"University of Toronto; Toronto Canada"},{"name":"Division of Haematology\/Oncology; Section of Neuro-Oncology; The Hospital for Sick Children; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,30]]},"reference":[{"key":"10.1002\/pbc.25573-BIB0001|pbc25573-cit-0001","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archneur.57.5.662","article-title":"National institutes of health consensus conference: Tuberous sclerosis complex","volume":"57","author":"Hyman","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1002\/pbc.25573-BIB0002|pbc25573-cit-0002","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1002\/pbc.25573-BIB0003|pbc25573-cit-0003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","article-title":"Subependymal giant cell astrocytoma: Diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012","volume":"49","author":"Roth","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1002\/pbc.25573-BIB0004|pbc25573-cit-0004","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.25573-BIB0005|pbc25573-cit-0005","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2009.02567.x","article-title":"Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature","volume":"16","author":"Adriaensen","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1002\/pbc.25573-BIB0006|pbc25573-cit-0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of Everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/pbc.25573-BIB0007|pbc25573-cit-0007","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejpn.2012.12.008","article-title":"Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations","volume":"17","author":"Jozwiak","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1002\/pbc.25573-BIB0008|pbc25573-cit-0008","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1002\/pbc.25573-BIB0009|pbc25573-cit-0009","unstructured":"http:\/\/ctep.cancer.gov"},{"key":"10.1002\/pbc.25573-BIB0010|pbc25573-cit-0010","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"10.1002\/pbc.25573-BIB0011|pbc25573-cit-0011","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/pbc.22298","article-title":"Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors","volume":"54","author":"Lam","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25573-BIB0012|pbc25573-cit-0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/088307389801300405","article-title":"Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis","volume":"13","author":"Torres","year":"1998","journal-title":"J Child Neurol"},{"key":"10.1002\/pbc.25573-BIB0013|pbc25573-cit-0013","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2176\/nmc.38.287","article-title":"Glioblastoma following radiotherapy in a patient with tuberous sclerosis","volume":"38","author":"Matsumura","year":"1998","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1002\/pbc.25573-BIB0014|pbc25573-cit-0014","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3171\/jns.1991.74.5.0701","article-title":"Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy","volume":"74","author":"Petronio","year":"1991","journal-title":"J Neurosurg"},{"key":"10.1002\/pbc.25573-BIB0015|pbc25573-cit-0015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/pbc.25573-BIB0016|pbc25573-cit-0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1016034910875","article-title":"Mixing during intravertebral arterial infusions in an in vitro model","volume":"58","author":"Lutz","year":"2002","journal-title":"J Neurooncol"},{"key":"10.1002\/pbc.25573-BIB0017|pbc25573-cit-0017","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mTOR inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"10.1002\/pbc.25573-BIB0018|pbc25573-cit-0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00280-009-1068-8","article-title":"Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents","volume":"65","author":"O'Reilly","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25573-BIB0019|pbc25573-cit-0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/pbc.25573-BIB0020|pbc25573-cit-0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1002\/pbc.25573-BIB0021|pbc25573-cit-0021","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/pbc.25573-BIB0022|pbc25573-cit-0022","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ki.1996.28","article-title":"The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients","volume":"49","author":"Murgia","year":"1996","journal-title":"Kidney Int"},{"key":"10.1002\/pbc.25573-BIB0023|pbc25573-cit-0023","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jcph.428","article-title":"Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation","volume":"55","author":"Somers","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/pbc.25573-BIB0024|pbc25573-cit-0024","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1345\/aph.1G706","article-title":"Posttransplant lymphoproliferative disorder","volume":"41","author":"Everly","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1002\/pbc.25573-BIB0025|pbc25573-cit-0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/TP.0b013e318277e344","article-title":"Characteristics of early and late PTLD development in pediatric solid organ transplant recipients","volume":"95","author":"Schober","year":"2013","journal-title":"Transplantation"},{"key":"10.1002\/pbc.25573-BIB0026|pbc25573-cit-0026","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/petr.12103","article-title":"Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: Incidence, clinical features and outcome","volume":"17","author":"Ramos","year":"2013","journal-title":"Pedatr Transplant"},{"key":"10.1002\/pbc.25573-BIB0027|pbc25573-cit-0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"10.1002\/pbc.25573-BIB0028|pbc25573-cit-0028","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","article-title":"CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation","volume":"25","author":"Maecker","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25573-BIB0029|pbc25573-cit-0029","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00467-011-1811-3","article-title":"Growth of kidney-transplanted pediatric patients treated with sirolimus","volume":"26","author":"Gonzalez","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1002\/pbc.25573-BIB0030|pbc25573-cit-0030","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00467-009-1215-9","article-title":"Growth failure associated with sirolimus: Case report","volume":"24","author":"Rangel","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1002\/pbc.25573-BIB0031|pbc25573-cit-0031","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11910-014-0441-0","article-title":"Targeted therapy in pediatric low-grade glioma","volume":"14","author":"Kilday","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1002\/pbc.25573-BIB0032|pbc25573-cit-0032","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/ern.13.48","article-title":"A critical review of mTOR inhibitors and epilepsy: From basic science to clinical trials","volume":"13","author":"Wong","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1002\/pbc.25573-BIB0033|pbc25573-cit-0033","volume-title":"Jasper's Basic Mechanisms of the Epilepsies [Internet]","author":"Wong","year":"2012","edition":"4"},{"key":"10.1002\/pbc.25573-BIB0034|pbc25573-cit-0034","unstructured":"ClinicalTrials.gov http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01713946"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25573","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.25573\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T09:03:09Z","timestamp":1596099789000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pbc.25573"}},"subtitle":["Minimal mTOR Doses for SEGA"],"short-title":[],"issued":{"date-parts":[[2015,4,30]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.25573","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4,30]]}}}